Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EPS (Weighted Average and Diluted) (2020 - 2025)

Sangamo Therapeutics (SGMO) has 7 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.11 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 237.5% year-over-year to -$0.11; the TTM value through Sep 2025 reached -$0.44, up 38.03%, while the annual FY2024 figure was -$0.49, 66.89% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.11 in Q3 2025 per SGMO's latest filing, down from -$0.07 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.12 in Q1 2023 and bottomed at -$0.66 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.25, with a median of -$0.29 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 3400.0% in 2021, then skyrocketed 140.0% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.25 in 2021, then decreased by 28.0% to -$0.32 in 2022, then decreased by 6.25% to -$0.34 in 2023, then surged by 64.71% to -$0.12 in 2024, then grew by 8.33% to -$0.11 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.11 in Q3 2025, -$0.07 in Q2 2025, and -$0.14 in Q1 2025.